Top Biotech Companies in NYC, NY (263)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.
Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.
Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Newer and acquired medicines grew 18% operationally in Q2 2026, while revenue excluding Comirnaty and Paxlovid rose 5% operationally in the same period. Excluding COVID products, 2025 revenue also increased 6% operationally, supported by growth in products such as Eliquis and Padcev.
Cost & Operational Efficiency: Management is pursuing additional savings to improve operational efficiency and support profitability. These cost-control efforts are intended to help the business transition away from pandemic-driven sales while supporting margins.
Innovation-Driven Growth: Investment in future growth includes $10.4 billion in internal R&D during 2025 and ongoing development in oncology and obesity. A broad pipeline and recent acquisitions are intended to offset declining COVID-19 sales and patent expirations if programs succeed.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.
Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.
Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Recent financial results highlight sustained top-line expansion with rising quarterly revenue and management increasing full‑year guidance, indicating momentum across 2025 and into 2026.
Diversified Revenue Streams: Growth is coming from both diagnostics and data licensing/AI applications, with testing volumes and data contracts expanding rather than reliance on a single line of business.
Customer Loyalty & Retention: Reported net revenue retention above 100% and sizable remaining contract value suggest existing pharmaceutical customers are deepening engagements.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Market Expansion: The platform’s reported research-site network scaled from hundreds in 2022 to 6,000+ sites across 50+ countries, alongside a broader base of 25+ sponsors. Feedback suggests recent partnerships helped extend reach to additional site networks.
Product Line Growth: Inato moved beyond its original marketplace into AI-powered patient pre-screening and AI site-selection, with ongoing workflow integrations. These additions indicate continued investment in broader clinical-trial capabilities.
Strategic Partnerships: Collaborations such as the RealTime eClinical Solutions agreement and integrations with CRIO and other providers are described as expanding distribution and deepening ecosystem ties. Feedback suggests these relationships open pathways to thousands of affiliated sites and embed the platform more fully in site workflows.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is reported to have nearly doubled during CEO Carolyn Starrett’s tenure beginning in 2021, alongside expansion of the real‑world data platform and commercial evidence services. This is the clearest direct indicator of commercial momentum even though underlying figures were not disclosed.
Market Expansion: International oncology research reach expanded markedly, with the network tripling in 2025 and then growing nearly 70% year over year by July 2026 to more than 50 sites across the UK, Germany and Japan, including a first partnership in Scotland. This points to broader geographic access and commercial reach.
Product Line Growth: Data assets and offerings have broadened, with the evidence base growing to more than six million patient records and launches such as the AI-enabled Telescope platform and expanded Panoramic datasets. These developments indicate deeper research utility and a wider product portfolio.
For people who believe eating healthier should be effortless and tasty, The Not Company is a Foodtech, that reinvents animal-based foods using only plants. Unlike traditional food businesses, our company uses technology to recreate the same products we love to eat in a natural, sustainable and affordable way, keeping it functional, easy to use and mouthwateringly delicious.
Pacira Pharmaceuticals is a specialty pharmaceutical company dedicated to postsurgical innovation.
Singer Equipment Company is a foodservice equipment and supplies distributor headquartered in Elverson, Pennsylvania. Established in 1918, it provides commercial kitchen design and construction, wholesale supply management, equipment, and related solutions to foodservice businesses nationwide. The company serves more than 5,000 customers annually, combining nationwide distribution capabilities with specialized expertise and personalized customer service for foodservice operators across the United...
Evvy is a female-founded startup building a new understanding of the female body. Our at-home vaginal microbiome test is the first to leverage metagenomic sequencing to help anyone with a vagina understand what’s up down there, why it matters, and what they can do about it. Why the vaginal microbiome? Turns out, at least 30% of people with vaginas suffer from imbalances...
Curia is a leading global contract research, development, and manufacturing organization (CDMO) with over 30 years of experience, guiding clients through the complexities of drug discovery, development, and manufacturing.
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. We are dedicated to making a meaningful impact in patients’ lives as well as the communities where we live and work. Our team is guided by our core values of collaboration, accountability, passion, respect, and integrity. Insmed...
Allentown is a global provider of laboratory equipment and integrated vivarium solutions for biomedical preclinical research and broader life sciences. The company engineers and manufactures animal housing systems, cages, airflow systems, and related lab equipment, with customer-specific design and engineering support. Its products and services help research institutions, pharmaceutical and biotechnology companies, and private laboratories operate research environments supporting drug...
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising...
Emergence's goal is to advance the science of agents and the creation of multi-agent systems for the Enterprise
Pernix Therapeutics develops and markets branded and generic pharmaceutical products for the pediatric market.
The Child Mind Institute is an independent national nonprofit dedicated to transforming the lives of children and families struggling with mental health and learning disorders. Our teams work every day to deliver the highest standards of care, advance the science of the developing brain and empower parents, professionals, and policymakers to support children when and where they need it most....
